Related Experiment Video
Updated: Aug 7, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
Postpartum anti-D: can we safely reduce the dose?
Bradley M Augustson1, Elizabeth A Fong, Dianne E Grey
1PathWest Laboratory Medicine WA, Perth, Western Australia, Australia. bradley.augustson@health.wa.gov.au
Objective:
To assess the potential for dose-reduction of prophylactic anti-D postpartum.
Design:
Retrospective audit of fetomaternal haemorrhage (FMH) quantitation by flow cytometry.
Participants And Setting:
5148 consecutive Rhesus D-negative women aged 15-45 years who had FMH estimation by flow cytometry at a central laboratory in Western Australia in the 65 months between 1 August 1999 and 31 January 2005.
Main Outcome Measures:
Quantitation of FMH volume for adequate prophylactic anti-D administration in a timely fashion.
Results:
90.4% (4651/5148) of the women had an FMH volume of 1.0 mL or less of Rh D-positive red cells, and 98.5% (5072/5148) had a volume of less than 2.5 mL. Only 0.4% of cases had an FMH volume of 6.0 mL or greater (range, 6.0-92.4 mL).
Conclusions:
This large retrospective audit shows that a currently available dose of 250 IU (50 mg) of anti-D would have been sufficient for 98.5% of the 5148 Rh D-negative women. On the basis of this evidence, a reduction in the recommended routine postpartum dose of anti-D from 625 IU to 250 IU when flow cytometric quantitation for FMH is available should be considered. Adopting such a strategy would ensure the ongoing provision of a valuable human blood product currently in limited supply.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

